NK/T-cell Lymphoma Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting nk/t-cell lymphoma clinical trials across 10 countries. Studies span Phase 2, Phase 1, Early Phase 1, Not Applicable. Top locations include Duarte, California, United States, New Haven, Connecticut, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


NK/T-cell Lymphoma Trials at a Glance

7 actively recruiting trials for nk/t-cell lymphoma are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Duarte, New Haven, and Boston. Lead sponsors running nk/t-cell lymphoma studies include Dren Bio, Memorial Sloan Kettering Cancer Center, and Chinese PLA General Hospital.

Browse nk/t-cell lymphoma trials by phase

Treatments under study

About NK/T-cell Lymphoma Clinical Trials

Looking for clinical trials for NK/T-cell Lymphoma? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new NK/T-cell Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about NK/T-cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Aggressive NK-cell LeukemiaLGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous Gamma-Delta T-Cell Lymphoma+10 more
Dren Bio200 enrolled37 locationsNCT05475925
Recruiting

A Registry for People With T-cell Lymphoma

T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+27 more
Memorial Sloan Kettering Cancer Center1,000 enrolled26 locationsNCT05978141
Recruiting
Early Phase 1

Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma

DLBCLNK/T-cell LymphomaPeripheral T-cell Lymphoma (PTCL)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine24 enrolled1 locationNCT07162012
Recruiting
Phase 2

A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma

NK/T-cell Lymphoma
Peking University Cancer Hospital & Institute57 enrolled3 locationsNCT07000617
Recruiting
Phase 1

RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies

CART TherapyNK/T-cell LymphomaCD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology10 enrolled1 locationNCT06732492
Recruiting
Not Applicable

PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma

NK/T-cell Lymphoma
Ruijin Hospital40 enrolled1 locationNCT05662540
Recruiting
Phase 2

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

Advanced LymphomaNewly DiagnosedNK/T-cell Lymphoma
Chinese PLA General Hospital10 enrolled1 locationNCT05833893